Paediatric B-cell precursor acute lymphoblastic leukaemia with t(1;19)(q23;p13): clinical and cytogenetic characteristics of 47 cases from the Nordic countries treated according to NOPHO protocols

Br J Haematol. 2011 Oct;155(2):235-43. doi: 10.1111/j.1365-2141.2011.08824.x. Epub 2011 Sep 9.

Abstract

The translocation t(1;19)(q23;p13)/der(19)t(1;19) is a risk stratifying aberration in childhood B-cell precursor acute lymphoblastic leukaemia (BCP ALL) in the Nordic countries. We have identified 47 children/adolescents with t(1;19)/der(19)t(1;19)-positive BCP ALL treated on two successive Nordic Society of Paediatric Haematology and Oncology (NOPHO) protocols between 1992 and 2007 and have reviewed the clinical and cytogenetic characteristics of these cases, comprising 1·8% of all cases. The translocation was balanced in 15 cases (32%) and unbalanced in 29 cases (62%). The most common additional chromosome abnormalities were del(9p), i(9q), del(6q), and del(13q). The median age was 7 years, the median white blood cell (WBC) count was 16 × 10(9)/l, and the female/male ratio was 1·2. The predicted event-free survival (EFS) at 5 and 10 years was 0·79, whereas the predicted overall survival (OS) at 5 and 10 years was 0·85 and 0·82, respectively. Nine patients had a bone marrow relapse after a median of 23 months; no patient had a central nervous system relapse. Additional cytogenetic abnormalities, age, gender, WBC count or whether the t(1;19) was balanced or unbalanced did not influence EFS or OS. Compared to cases with t(12,21) and high hyperdiploidy, EFS was similar, but overall survival was worse in patients with t(1;19)/der(19)t(1;19) (P = 0·004).

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Aneuploidy
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Child
  • Child, Preschool
  • Chromosomes, Human, Pair 1 / genetics*
  • Chromosomes, Human, Pair 1 / ultrastructure
  • Chromosomes, Human, Pair 12 / genetics
  • Chromosomes, Human, Pair 12 / ultrastructure
  • Chromosomes, Human, Pair 19 / genetics*
  • Chromosomes, Human, Pair 19 / ultrastructure
  • Chromosomes, Human, Pair 21 / genetics
  • Chromosomes, Human, Pair 21 / ultrastructure
  • Disease-Free Survival
  • Finland / epidemiology
  • Follow-Up Studies
  • Humans
  • Iceland / epidemiology
  • Infant
  • Kaplan-Meier Estimate
  • Oncogene Proteins, Fusion / genetics
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / epidemiology*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Prognosis
  • Recurrence
  • Scandinavian and Nordic Countries / epidemiology
  • Translocation, Genetic*
  • Treatment Outcome

Substances

  • Oncogene Proteins, Fusion
  • TCF3-PBX1 fusion protein, human